cancer

Johnson & Johnson (NYSE:JNJ) has been directed to pay $65.6 million to a Minnesota woman who was diagnosed with cancer following the use of their talcum powder. What Happened: A Minnesota jury awarded Anna Jean Houghton Carley, a mother of three, $65.5 million on Friday. Carley contended...

Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. • Merck & Co stock is showing upward bias. What’s...

Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ:GILD), due to futility. • Arcus Biosciences stock is among today’s weakest performers. Why is RCUS stock dropping...

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) released topline data on Wednesday from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classical epidermal growth factor receptor (EGFR) mutations (NCMs). • BDTX stock is showing notable...

The U.S. Food and Drug Administration approved Genmab A/S (NASDAQ:GMAB) Epkinly (epcoritamab-bysp) on Tuesday with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory...

Nuvalent, Inc. (NASDAQ:NUVL) on Monday reported topline results from its ALKOVE-1 Phase 1/2 trial. The study evaluated neladalkib in tyrosine kinase inhibitor (TKI)-pretreated patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The company said the recommended Phase 2 dose was...

President Donald Trump‘s $3.3 trillion domestic agenda bill, passed by House Republicans on Thursday, includes a significant but little-noticed victory for pharmaceutical companies that will cost taxpayers nearly $5 billion over the next decade. What Happened: The legislation expands...

Cathie Wood, the founder, CEO, and CIO of Ark Invest, underscored the application of artificial intelligence in the healthcare sector by sharing new research by Mass General Brigham, citing the discovery of cancer survival using facial photograph analysis. What Happened: Wood reiterated her earlier...

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares are trading lower Friday following the release of updated interim data from its Phase 1/1b trial of ficerafusp alfa in combination with pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma. What To know: The...

Former U.S. President Joe Biden has been diagnosed with an aggressive form of prostate cancer that has metastasized to his bones, as reported by Reuters on Sunday. What Happened: The diagnosis was made on Friday after Biden, 82, experienced urinary symptoms. He and his family are currently...

Summit Therapeutics Inc. (NASDAQ:SMMT) on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indication based on the results of the Phase 3 trial, HARMONi-2 or AK112-303. On Friday,...

Pliant Therapeutics, Inc. (NASDAQ:PLRX) released on Monday data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation trial of PLN-101095, in combination with Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab), in patients with immune...

H.C. Wainwright & Co. initiated coverage on Thursday for Perspective Therapeutics, Inc. (NASDAQ:CATX), a clinical-stage biotechnology company advancing “targeted radiotherapy agents” for cancer treatment. Analyst Robert Burns initiated a Buy rating and a price target of $10. The...

On Monday, the FDA accepted the supplemental biologics license application (sBLA) for Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment option for adult and pediatric patients (12 years and older)...

On Monday, Pfizer Inc (NYSE:PFE) revealed topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) for...